Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602745 · ClinicalTrials.gov registry record · Phase 3
S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT00602745 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 61 participants.
The verdict
NCT00602745, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether S-1 increases overall survival when compared to 5-Fluorouracil (5-FU) in patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy. The secondary objectives are to compare: progression free survival, overall response rate, clinical benefit and improvement in tumor related symptoms and also to assess overall safety and pharmacokinetics of S-1.
Interventions
- DRUG 5-Fluorouracil
- DRUG S-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602745
The ClinicalTrials.gov registry entry for NCT00602745 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5-Fluorouracil is the first listed.
NCT00602745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602745 about?
NCT00602745 is a clinical study titled "S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen". The primary objective of this study is to determine whether S-1 increases overall survival when compared to 5-Fluorouracil (5-FU) in patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy. The secondary objectives are to compare: progression free survival, ov...
What is the current status of trial NCT00602745?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2008-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00602745?
The interventions under investigation include: 5-Fluorouracil (DRUG), S-1 (DRUG).
Who is sponsoring clinical trial NCT00602745?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.